" class="no-js "lang="en-US"> Stephen A. Williams - Medtech Alert
Thursday, March 28, 2024
Stephen A. Williams

Stephen A. Williams

About Stephen A. Williams

Steve Williams is currently responsible for Clinical R&D, Medical Affairs and Regulatory and Quality. He joined SomaLogic in 2009 as Chief Medical Officer responsible for the clinical application of the SomaScan®​ Platform and also had roles in launching the Life Sciences commercial business, assay development and bioinformatics. Prior to SomaLogic, Dr. Williams co-founded the pharma consultancy Decisionability, LLC in 2007 and authored the book “Decisionability.” From 1989-2007, he worked at Pfizer, Inc., initially in Experimental Medicine and later as Vice President and Worldwide Head of Clinical Technology. From 2003-2007, he was on the National Advisory Council for Biomedical Imaging and Bioengineering at the National Institutes of Health. He helped to launch the Alzheimer’s Disease Neuroimaging (ADNI) study and to form the FDA-FNIH-PhRMA biomarker consortium. He led or co-led the PhRMA position papers on “proof of concept,” surrogate endpoints and evidentiary standards for biomarkers and diagnostics.

Dr. Williams has degrees in physiology, medicine and surgery, and a doctorate in medicine and physiology from Charing Cross and Westminster Medical School (now a part of Imperial College, London). He also obtained training in diagnostic imaging at the University of Newcastle Upon Tyne.

Related Story

Major Journal Publishes Landmark Proteomics Study Demonstrating Development of an Unprecedented New Clinical Cardiovascular Risk Test

April 13 2022

In one of the largest proteomic studies ever conducted and published April 6 in the […]

SomaLogic to Provide 210 Million Protein Measurements to EPIC Researchers to Better Understand and Predict Cancer Development

March 22 2022

SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced that the company will […]